WuXi Biologics
Offering End-to-End Solutions
“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry
To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics.
projects in pre-clinical development stage
projects in early-phase clinical trials
projects in late-phase clinical trials
projects in commercial manufacturing
Integrity, Dedication, Working Together & Sharing Success
Exceed customers’ expectations, maximize the value for our customers, and win customers’ loyalty with a 100% customer retention rate.
Take the initiative to promote a positive work environment where doing the right thing is the standard. Be positive and enthusiastic, approach challenges with energy and optimism.
Pursue focus and expertise, and optimize processes in order to deliver excellent results. Relentlessly drive learning, accumulation, improvement and innovation.
Drive effective execution of each project and objective, focusing on solutions and results.
Engage in collaboration and mutual development with an open and win-win mindset by sharing resources and leveraging the complementary advantages of each.
Demonstrate flexibility and ability to embrace change. Adapt quickly to transformational and innovative conditions with a strong commitment to breakthroughs and development.
September 2021 — WuXi Biologics’ partner Gloria Biosciences announced that its Zimberelimab, a fully human anti-PD-1 monoclonal antibody, has been approved by China National Medical Product Administration (NMPA). This is the second IND-to-commercial product globally as well as the first in China enabled by WuXi Biologics.
December 2021 — WuXi Biologics’ partner CStone announced that its sugemalimab, anti-PD-L1 monoclonal antibody, has been approved by China National Medical Product administration (NMPA). This is the fourth commercial product in China enabled by WuXi Biologics.
IMPAPC Bioprocessing Excellence in Antibody & ADC Therapeutics Manufacturing and in Viral Clearance and Safety in Greater China Region
Most Outstanding Company in Hong Kong Healthcare Sector by Asiamoney
InnoESG ESG Prize
“Best Payments and Collection Solution” by The Asset
August 2019 –The first robotic aseptic filling facility for biologics in China, has achieved GMP release.
November 2019 - Launch GMP production of ADC drug substance and product in the integrated biologics conjugation solution center.
“2019 Golden Stock”&“Best IR Award”from ZhiTong Finance and Tonghuashun Finance
“Best IR Award for Hong Kong Listed Companies (H share)” from New Fortune
April 2018 –WuXi Biologics began global layout (Ireland, Singapore and the U.S.).
Hong Kong Equity Issue from IFR Asia
Best Block Trade from The Asset
"2018 Golden Stock”&“Most Valuable Healthcare Stock”from ZhiTong Finance and Tonghuashun Finance
Best IPO Award and Best Investor Relations Award 2017 from "Chinese Financial Market"
2017 Most Popular New Stock from ZhiTong Finance and Tonghuashun Finance
December 2015 - Formed strategic alliance with AstraZeneca to expedite development of AstraZeneca’s innovative biologics portfolio in China.
May 2014 - Became the first company in China to manufacture biologics for clinical trials in the U.S.
June 2013 – Formed the first innovative antibody drug conjugate development and manufacturing partnership in China with Ambrx and Zhejiang Medicine.
November 2013 – Completed the first 2,000 L disposable bioreactor run using an NS0 cell line, marking an industry milestone.
October 2012 - The Wuxi site was put into operation as the first cGMP biologics manufacturing facility in China.
January 2011 – Began mission of providing single-source, open access technology platforms for biologics by building facilities and laboratories in Shanghai and Wuxi for the discovery, development, testing and manufacturing of biologics
May 2010 - WuXi Biologics Co., Ltd. was registered in Wuxi city, Jiangsu Province, China.
As a leading global open-access biologics technology platform, WuXi Biologics is committed to the highest standards of ethics and integrity. Employees, officers and directors strive to deal honestly, ethically and fairly with our suppliers, customers, competitors, employees and the communities we serve worldwide. Statements regarding the Company’s products and services must not be false, misleading, deceptive or fraudulent. WuXi Biologics strives to conduct business with individuals and organizations who share our commitment to highest ethical standards and who operate in a socially and environmentally responsible manner..
In line with that commitment, the Company expects and encourages its employees, customers, suppliers and other stakeholders who have concerns about any suspected misconduct or malpractice within the Company to come forward and voice those concerns through the whistleblowing channel. Compliance reporting: IA_biologics@wuxibiologics.com,Compliance_Biologics@wuxibiologics.com
《Anti-Corruption Policy of WuXi Biologics》 《WHISTLEBLOWING AND INVESTIGATION》 《THE CONFLICT OF INTEREST POLICY》
《CODE OF BUSINESS CONDUCT AND ETHICS》 《CODE OF BUSINESS CONDUCT AND ETHICS of WuXi Biologics Business Partner》
“Our purpose in business is to enable innovation for our global partners, who keep us at the top of their confidence. IP is our shared lifeline. We guard it at WuXi Biologics with our founding principles of integrity, world-class security, zero tolerance policies, and relentless pursuit of justice against any criminal act. This is our highest priority, and we must hold ourselves accountable. We are determined to earn the trust of our partners by committing to success together.”
Intellectual Property Protection is the foundation of trust between WuXi Biologics and our global customers. To that end, we have established the most stringent policies in China and in U.S. for the protection of intellectual property and for prosecution of IP violations. We guard IP with founding principles of integrity, world-class security, zero-tolerance policy enforcement, and relentless pursuit of justice against any criminal act.
We are dedicated to implementing sustainable and eco-friendly business practices by building a comprehensive and integrated Environmental, Health and Safety (EHS) management system, sourcing ethically, advocating reduced energy consumption, minimizing effluent, and acting responsibly to tackle climate change and reduce operational impact on the environment.
※ In 2019, Phase I of the Mashan Base, Wuxi Site was awarded the ISO14001 Environmental Management System Certificate.
Adopt more energy-saving technologies and equipment, such as disposable bioreactors
Use water sparingly and reuse for multiple purposes
Encourage the use of renewable materials and recycling
Reduce greenhouse gas emissions, untreated waste gases and waste discharge. Enforce noise pollution regulations
WuXi Biologics Volunteer Association (China Region) Formed
WuXi Biologics Charity Foundation Donates RMB 10 Million to Flood Relief Efforts Across Henan, China
Bring Our Light of Hope to the Darkness
DEI trainings in the workplace: WuXi Biologics further fosters DEI and sustainability
Participate in the Protecting Endangered Wild Animals charitable project led by World Animal Protection and become a signatory to the Wild Animal Friendly undertaking as a pharmaceutical enterprise
Introduced the science exhibition area to educate on rare and orphan drug diseases and drug development
Organize routine blood donations and actively undertake social responsibility through company-sponsored programs
Hold summer Open Access Week events to provide training to better understand the healthcare industry and drug development
Diversity, Equity and Inclusion
Corporate Compliance and Anti-Corruption
Quality as Foundation
Diversity, Equity and Inclusion is critical to the sustainable growth and innovation of our business
Recruit employees based on their professional and academic achievements regardless of religion, disability, age, race, color, sex, gender identity, sexual orientation, or marital status
Adhere to equal employment opportunity to advance a diverse workforce and to create an equal and inclusive corporate culture
Establish our own compliance management system
Conduct various trainings such as ethical standards for all employees
“Zero tolerance” for bribery and corruption
Value honesty and trustworthy business conduct
《Responsible marketing policy of WuXi Biologics》
《WuXi Biologics Forges a Culture of Sustainability, Integrity and Compliance》
Build a world-class quality system to enable global partners
Establish a 7-step workflow to strictly control every segment
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?